Development of Circadian Rhythms on Chip

Projektinformationen

CircaCHIP

ID Finanzhilfevereinbarung: 813109

DOI

10.3030/813109

Projekt abgeschlossen

EK-Unterschriftsdatum 28 Mai 2018

Startdatum 1 Juni 2018

Enddatum 30 November 2019

Finanziert unter

• EXCELLENT SCIENCE - European Research Council (ERC)

Gesamtkosten

€ 149 969,00

EU-Beitrag

€ 149 969,00

Koordiniert durch

THE HEBREW UNIVERSITY OF JERUSALEM
Israel

Periodic Reporting for period 1 - CircaCHIP (Development of Circadian Rhythms on Chip)

Berichtszeitraum: 2018-06-01 bis 2019-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

The natural cycle of day and night on our planet introduces inherent cycles to our local environment. These cyclical differences in light, temperature and food availability produce hormonal oscillations in higher organisms that allow us to better prepare for morning activity as well as prolonged fasting during the night. Disruption of these circadian rhythms leads to metabolic syndrome, obesity and type-2 diabetes. These metabolic diseases are pronounced in nightshift workers and are exacerbated by widespread light pollution. While current work on circadian rhythms focuses on animal models, differences in metabolism, physiology and genetics between humans and rodents make it difficult to translate these findings to clinical results. In this project we sought to develop a three-dimensional model of the human liver that maintains natural physiological rhythms through the oscillations of day and night hormones, mimicking human physiology.

Our model successfully captured metabolic oscillations in a 3D model of the human liver, as well as the onset of circadian rhythms in a 3D model of a developing embryo. This proprietary technology was patented at the Hebrew University of Jerusalem and licensed to Tissue Dynamics, a groundbreaking Organ-on-Chip company developing the first physiological bioanalyzer. Our technology presents a unique opportunity for the study of time-of-day dependent drug toxicity and efficacy, as well as a critical tool for the design of new pharmaceutical interventions for metabolic diseases such as obesity and type-2 diabetes.